COMP <GO>
IOVA vs ABBV // RETURN ON INVESTED CAPITAL (ROIC)
Iovance Biotherapeutics Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: IOVA 4
— ABBV 10
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: ABBV
LAST: $8.48 (-11.30%) • MKT CAP: $4.33B
roic
-35.00%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
roic
29.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IOVA VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IOVA | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 34.30% | 70.20% | -35.90 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -35.00% | 29.00% | -64.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -7.76% | 3.47% | -11.23 | ABBV | /fcf-yield <GO> |
| Operating Margin | -60.00% | 24.60% | -84.60 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 6.90% | -66.90 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 60.60% | 8.60% | +52.00 | IOVA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 7.08 | 5.33 | +1.75 | IOVA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 7.40% | -0.50 | IOVA | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 30.4 | 72.8 | -42.40 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.99 | 1.15 | -0.16 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 33.0x | 113.1x | -80.10 | IOVA | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.33B | $513.86B | -$509.53B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IOVA REV | ABBV REV | IOVA GROSS % | ABBV GROSS % | IOVA FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $263.5M | $61.16B | 34.3% | 70.2% | -$336.2M | $17.82B |
| FY 2024 | $164.1M | $56.33B | 43.2% | 70.0% | -$364.0M | $17.83B |
| FY 2023 | $1.2M | $54.32B | 44.0% | 44.0% | -$361.9M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IOVA // BETA 0.99
ABBV // BETA 1.15